- Home
- CZNC vs PGEN Comparison
CZNC vs PGEN Comparison
Compare CZNC & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | PGEN |
|---|---|---|
| Founded | 1864 | 1998 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.4M | 2.8B |
| IPO Year | 2009 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CZNC | PGEN |
|---|---|---|
| Price | $25.79 | $7.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $23.50 | $8.33 |
| AVG Volume (30 Days) | 53.1K | ★ 4.0M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.81 | 0.03 |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $3.11 | $1,115.92 |
| Revenue Next Year | N/A | $81.04 |
| P/E Ratio | ★ $32.01 | $262.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.87 | $2.99 |
| 52 Week High | $26.37 | $7.95 |
Technical Indicators
Market Signals| Indicator | CZNC | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 53.35 | 66.75 |
| Support Level | $24.89 | $6.57 |
| Resistance Level | $26.15 | N/A |
| Average True Range (ATR) | 0.51 | 0.28 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 54.30 | 81.41 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.